|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5665986||1407780||2017||3 صفحه PDF||ندارد||دانلود کنید|
â¢First case of NDM-1-producing Leclercia adecarboxylata in Spain and second in the worldâ¢The isolate was resistant to beta-lactams, quinolones, trimetroprim-sulfametoxazol, gentamicin and tobramycin.â¢Plasmid encoding blaNDM-1 belongs to the incompatibility group X3, a described vector for NDM-1 dissemination in China.â¢Species of uncertain clinical relevance could be vehicles for resistance determinants.
We describe the case of NDM-1-producing Leclercia adecarboxylata recovered from the clinical sample of a patient hospitalized for a trauma-related injury to his foot. The isolate was resistant to all beta-lactams, quinolones, trimetroprim-sulfametoxazol, gentamicin and tobramicyn. The blaNDM-1 gene was located in a conjugative plasmid that also contained the blaSHV-12 gene and was preceded by a disrupted insertion sequence of ISAba125. The plasmid belongs to the incompatibility group X3, which is known to be an important vector for NDM-1 dissemination in China. This is the first reported case of NDM-1Â L. adecarboxylata in our country and evidences that species of uncertain clinical relevance can act as hidden sources of clinically important resistance determinants.
Journal: Diagnostic Microbiology and Infectious Disease - Volume 88, Issue 3, July 2017, Pages 268-270